Doctors enter biotech with strong training, high credibility, and real-world experience. They also enter with blind spots.
Clinical medicine rewards speed, independence, and decisive action. Biotech rewards alignment, patience, and structured decision-making. The gap between those worlds creates predictable mistakes.
Roughly 1 in 3 physicians who move into industry roles report difficulty adapting during their first year, according to workforce transition surveys. The issue is not capability. It is translation.
Dr. Leigh Beveridge, Australia, has worked with physicians making this shift and has seen the same patterns repeat.
“The first instinct is to treat biotech like an extension of the clinic,” he says. “It isn’t. The pace, the incentives, and the decision process are completely different.”
Mistake #1: Expecting Fast Decisions
In medicine, decisions happen quickly. A patient presents. You assess. You act.
In biotech, decisions move through layers:
- Data review
- Cross-functional alignment
- Regulatory consideration
- Risk assessment
This slows everything down.
One physician entering a development team pushed for rapid protocol changes after seeing early data.
“They were right about the issue,” he says. “But they underestimated how many groups needed to align before anything could change.”
Speed without alignment creates friction.
Fix:
Redefine progress. In biotech, progress includes alignment. Map out who needs to agree before action happens.
Mistake #2: Overvaluing Individual Expertise
Doctors are trained to rely on their own judgment. That works in clinical settings.
In biotech, no single perspective is enough.
Programs depend on:
- Clinicians
- Statisticians
- Regulatory experts
- Operations teams
Each group holds part of the answer.
“I’ve seen strong physicians struggle because they tried to own the decision alone,” he says. “The better approach is to integrate perspectives.”
Expertise shifts from individual to collective.
Fix:
Ask for input early. Treat decision-making as a shared process, not a solo call.
Mistake #3: Misunderstanding What “Good Data” Means
Clinical experience builds intuition. That intuition does not always match how data is evaluated in trials.
Doctors often focus on individual patient responses. Trials focus on population-level outcomes.
One physician highlighted a strong patient response in a small subgroup.
“We had to step back and ask whether that subgroup was pre-specified,” he says. “It wasn’t. That changed how we interpreted the result.”
Biotech requires statistical discipline.
Fix:
Focus on predefined endpoints. Learn how trial design shapes interpretation. Do not overreact to isolated results.
Mistake #4: Underestimating the Role of Regulation
In clinical practice, guidelines inform decisions. In biotech, regulators shape them.
Every major move must align with regulatory expectations.
This includes:
- Trial design
- Endpoint selection
- Safety monitoring
- Submission strategy
Ignoring this slows programs.
“I’ve seen teams propose strong ideas that regulators would never accept,” he says. “That creates rework and delays.”
Regulation is not a barrier. It is part of the system.
Fix:
Understand regulatory frameworks early. Ask how each decision will be viewed by agencies.
Mistake #5: Communicating Like a Clinician, Not a Leader
Doctors explain complex cases clearly. That skill helps. It is not enough.
Biotech requires communication across functions. Each group has different priorities.
- Clinicians focus on outcomes
- Statisticians focus on validity
- Executives focus on risk and value
Messages must adapt.
In one meeting, a physician presented detailed clinical reasoning.
“It was accurate,” he says. “But it didn’t answer the question the team needed to decide on.”
Clarity depends on context.
Fix:
Start with the decision. Frame communication around what the audience needs to act.
Mistake #6: Ignoring Operational Constraints
Clinical thinking focuses on what should happen medically. Biotech must also consider what can happen operationally.
Constraints include:
- Trial site capacity
- Patient recruitment
- Budget limits
- Timeline pressure
One physician designed a protocol that required frequent patient visits.
“It made sense medically,” he says. “But it reduced enrollment because patients couldn’t commit to the schedule.”
Good ideas fail when they ignore execution.
Fix:
Test feasibility early. Ask how decisions affect patients, sites, and timelines.
Mistake #7: Expecting Immediate Impact
In clinical practice, outcomes are visible quickly.
In biotech, timelines stretch for years.
A trial may take:
- 2–3 years to complete
- 1–2 years for analysis and approval
This delay changes motivation.
“Some physicians feel disconnected at first,” he says. “They don’t see immediate patient impact.”
The impact is real. It is delayed.
Fix:
Shift perspective. Focus on long-term outcomes. Track progress through milestones, not immediate results.
Mistake #8: Not Asking Enough Questions
Doctors are trained to provide answers. In biotech, asking better questions matters more.
Key questions include:
- What decision are we making?
- What data supports it?
- What risks remain?
- What happens if we’re wrong?
“I’ve seen people try to prove their point instead of testing it,” he says. “That limits progress.”
Questions drive clarity.
Fix:
Approach discussions with curiosity. Prioritize understanding over proving.
What Successful Transitions Look Like
Physicians who adapt well make a few key shifts:
- From speed to structure
- From individual to team-based thinking
- From intuition to data discipline
- From action to alignment
They keep their clinical insight. They adjust how they apply it.
Actionable Transition Plan
Doctors entering biotech can accelerate adaptation with a few steps.
1. Learn the System
Understand how decisions flow across teams. Map the process.
2. Study Trial Design
Know how endpoints, controls, and populations shape outcomes.
3. Build Cross-Functional Relationships
Spend time with non-clinical teams. Learn how they think.
4. Practice Structured Communication
State the problem, the data, and the decision clearly.
5. Accept Slower Timelines
Progress is measured differently. Adjust expectations.
6. Seek Mentorship
Learn from others who have made the transition.
The Bottom Line
The move from medicine to biotech is not a step up or down. It is a shift in system.
Doctors bring valuable insight. That insight becomes powerful when paired with structure, collaboration, and discipline.
Dr. Leigh Beveridge, Australia, puts it directly: “You don’t need to change who you are as a physician. You need to change how you operate inside the system.”
The difference between struggling and succeeding is not intelligence.
It is adaptation.
